BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20441244)

  • 1. Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study.
    Graff GR; McNamara J; Royall J; Caras S; Forssmann K
    Clin Drug Investig; 2010; 30(6):351-64. PubMed ID: 20441244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
    Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
    Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
    Kuhn RJ; Gelrud A; Munck A; Caras S
    Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
    Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
    Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
    Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
    Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Maguiness K; Graff GR; Boyd D; Beckmann K; Caras S
    J Cyst Fibros; 2009 Dec; 8(6):370-7. PubMed ID: 19815466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT.
    Van de Vijver E; Desager K; Mulberg AE; Staelens S; Verkade HJ; Bodewes FA; Malfroot A; Hauser B; Sinaasappel M; Van Biervliet S; Behm M; Pelckmans P; Callens D; Veereman-Wauters G
    J Pediatr Gastroenterol Nutr; 2011 Jul; 53(1):61-4. PubMed ID: 21694537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
    Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
    Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study.
    Colombo C; Fredella C; Russo MC; Faelli N; Motta V; Valmarana L; Longo L; D'Orazio C
    Pancreas; 2009 Aug; 38(6):693-9. PubMed ID: 19531972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.
    Thorat V; Reddy N; Bhatia S; Bapaye A; Rajkumar JS; Kini DD; Kalla MM; Ramesh H
    Aliment Pharmacol Ther; 2012 Sep; 36(5):426-36. PubMed ID: 22762290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis.
    Santini B; Antonelli M; Battistini A; Bertasi S; Collura M; Esposito I; Di Febbraro L; Ferrari R; Ferrero L; Iapichino L; Lucidi V; Manca A; Pisconti CL; Pisi G; Raia V; Romano L; Rosati P; Grazioli I; Melzi G
    Dig Liver Dis; 2000; 32(5):406-11. PubMed ID: 11030186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres--an open randomised crossover preference study.
    Patchell CJ; Desai M; Weller PH; Macdonald A; Smyth RL; Bush A; Gilbody JS; Duff SA
    J Cyst Fibros; 2002 Dec; 1(4):287-91. PubMed ID: 15463829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis.
    Trapnell BC; Strausbaugh SD; Woo MS; Tong SY; Silber SA; Mulberg AE; Leitz G
    J Cyst Fibros; 2011 Sep; 10(5):350-6. PubMed ID: 21632288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
    Whitcomb DC; Bodhani A; Beckmann K; Sander-Struckmeier S; Liu S; Fuldeore M; Pollack PF; Khurmi RP
    Pancreas; 2016; 45(5):679-86. PubMed ID: 26495784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liprotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis.
    Borowitz D; Stevens C; Brettman LR; Campion M; Wilschanski M; Thompson H;
    J Pediatr Gastroenterol Nutr; 2012 Feb; 54(2):248-57. PubMed ID: 22266487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term experience with ZENPEP in infants with exocrine pancreatic insufficiency associated with cystic fibrosis.
    Wooldridge JL; Schaeffer D; Jacobs D; Thieroff-Ekerdt R
    J Pediatr Gastroenterol Nutr; 2014 Nov; 59(5):612-5. PubMed ID: 25050848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Pancrelipase Therapy on Exocrine Pancreatic Insufficiency Symptoms and Coefficient of Fat Absorption Associated With Chronic Pancreatitis.
    Barkin JA; Barkin JS
    Pancreas; 2021 Feb; 50(2):176-182. PubMed ID: 33560089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of Creon® micro in children with exocrine pancreatic insufficiency due to cystic fibrosis.
    Kashirskaya NY; Kapranov NI; Sander-Struckmeier S; Kovalev V
    J Cyst Fibros; 2015 Mar; 14(2):275-81. PubMed ID: 25066363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two pancreatic enzyme products for exocrine insufficiency in patients with cystic fibrosis.
    Taylor CJ; Thieroff-Ekerdt R; Shiff S; Magnus L; Fleming R; Gommoll C
    J Cyst Fibros; 2016 Sep; 15(5):675-80. PubMed ID: 27013382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study.
    Brady MS; Garson JL; Krug SK; Kaul A; Rickard KA; Caffrey HH; Fineberg N; Balistreri WF; Stevens JC
    J Am Diet Assoc; 2006 Aug; 106(8):1181-6. PubMed ID: 16863712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.